Navigation Links
Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Date:12/8/2008

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Roche has dosed the first patient in a Phase 1 pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze Technology of a biologic directed to a Roche exclusive target. This has triggered a milestone payment under the agreement.

Roche has also selected an additional exclusive target under the existing license and collaboration agreement. Under the terms of the agreement, Roche will pay Halozyme for exclusive, global rights for the application of its hyaluronidase enzyme, rHuPH20, to a fourth biologic target selected by Roche.

"Roche and Halozyme have successfully completed the necessary drug product formulation and preclinical studies required to initiate a clinical trial. Entering the clinic is a significant achievement and demonstrates Roche's strong commitment to a successful partnership," said Jonathan Lim, M.D., Halozyme's President and CEO. "We are very pleased with the progress that is being made through our collaboration. Roche is a global leader in the development of biologics and we are excited that they have selected a fourth exclusive target, in addition to the three already under development, further validating Halozyme's core technology."

Roche has also maintained its rights to other targets covered in the license and collaboration agreement. An aggregate payment of $10.25 million will be made to Halozyme for commencing a Phase 1 clinical trial, exercising exclusive global rights to a fourth biologic target and for annual maintenance fees.

Halozyme also announced that it has entered into a supply agreement with Roche to provide rHuPH20 for use in formu
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
2. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
3. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
7. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
8. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
9. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
10. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
11. Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... ORLANDO, Fla. , Aug. 27, 2014 By ... Challenge, you,re likely not living on this planet. The awareness ... social consciousness and has helped to raise over $88.5 Million ... are getting involved and some companies are starting to as ... in Orlando, Florida , who actually works ...
(Date:8/27/2014)... Aug. 27, 2014 ISPE , the ... has released a preview of its Drug Shortages ... avoid drug shortages and maintain a robust and reliable ... The Plan, a first for the industry, was developed ... members and describes how industry can best prevent drug ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Global Heart Valve Repair ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart Valve Repair ... human heart which control the flow of blood ... heart valve diseases such as valvular stenosis, valvular ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 2ISPE Releases First Look at its Plan to Prevent Drug Shortages 3ISPE Releases First Look at its Plan to Prevent Drug Shortages 4Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 24 Schering-Plough Corporation (NYSE: SGP ... selective adenosine2a receptor antagonist, met the primary endpoint ... suffering from moderate to severe Parkinson,s disease experiencing ... The trial results were presented today at the ...
... , Dear President-Elect Obama:, , ... will start with billions of dollars,earmarked for stem cell research. ... is the voice of the Repair Stem Cell research and,treatment ... federal,funding support for our industry and the medical and scientific ...
Cached Medicine Technology:Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2
(Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... by Transparency Market Research "Ablation Technologies Market (Applications: ... Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - Global ... 2014 - 2020," the global ablation technologies market ... and is estimated to reach a market worth ...
(Date:8/27/2014)... new analysis of clinical trial participation in the largest ... found participants are not representative of the larger patient ... Hospital cardiologist Dr. Jay Udell. The study authors call ... the wider population, and suggest the use of broader ... participation. , "We know that clinical trials can be ...
(Date:8/27/2014)... the onset of a cancer defense mechanism known ... Cancer Center are leveraging it in a new ... cell death rather than survival. The novel treatment ... referred to as the "Trash Man" due to ... autophagy. Results from preclinical experiments suggest this experimental ...
(Date:8/27/2014)... Disability (CLD) has received a two-year, $600,000 grant ... the Health Resources and Services Administration to support ... at improving services for children and youth with ... project, CLD worked with an Autism Advisory Council ... resulting plan addresses priorities of increased awareness of ...
(Date:8/27/2014)... (Lebanon, NH 8/27/14)Dartmouth cancer researchers developed and tested ... and environmental interactions that contribute to disease as ... , The approach fills a gap in ... from complex interactions among genetic and environmental factors. ... relevant interactions versus those that reflect chance combinations ...
Breaking Medicine News(10 mins):Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Promising new cancer therapy uses molecular 'Trash Man' to exploit a common cancer defense 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
... colleagues from the Institute of Child Health will be studying ... The study will focus on the changes in their brain ... identify and understand the problems in their brain which could ... study is being funded by the Action Medical Research, UK. ...
... grow and currently affects more that 18 million ... need for alternative diabetes therapies with earlier more ... of insulin by the lung may provide an ... alternative insulin delivery systems must meet certain pharmacokinetic ...
... as the Breast Cancer Awareness Month. It is a sad ... and mortality associated with breast cancer//, very few men and ... risk factors and what is to be done in case ... Lauder, founder and president of the Breast Cancer Research Foundation, ...
... Los Angles have taken a major step forward in the ... the development of prostate cancer in animals//. ,The antibody ... and according to Dr. Robert E. Reiter, a professor of ... study's senior author it tells the cancer that it is ...
... known to express endogenous peptide antibiotics called defensins, ... active against bacteria, fungi and viruses//. ... of Nature, describes plectasin-the first defensin to be ... nigrella. Plectasin has primary, secondary and tertiary structures ...
... the deadly HIV/AIDS is accelerating in China with 126,808 ... patients, according to latest health reports//. Experts estimate that ... 80,000 AIDS patients. ,This is considerably higher than the ... over a margin of 19,818. In addition, the patients ...
Cached Medicine News:Health News:New Research To Study Brain Changes In Premature Births 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Mushroom found to be a source of a new antibiotic: Plectasin 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: